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Acute ketamine dysregulates task-related
gamma-band oscillations in thalamo-cortical
circuits in schizophrenia
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*These authors contributed equally to this work.
Hypofunction of the N-methyl-D-aspartate receptor (NMDAR) has been implicated as a possible mechanism underlying cognitive
deﬁcits and aberrant neuronal dynamics in schizophrenia. To test this hypothesis, we ﬁrst administered a sub-anaesthetic dose of
S-ketamine (0.006mg/kg/min) or saline in a single-blind crossover design in 14 participants while magnetoencephalographic data
were recorded during a visual task. In addition, magnetoencephalographic data were obtained in a sample of unmedicated ﬁrst-
episode psychosis patients (n = 10) and in patients with chronic schizophrenia (n = 16) to allow for comparisons of neuronal
dynamics in clinical populations versus NMDAR hypofunctioning. Magnetoencephalographic data were analysed at source-level in
the 1–90Hz frequency range in occipital and thalamic regions of interest. In addition, directed functional connectivity analysis was
performed using Granger causality and feedback and feedforward activity was investigated using a directed asymmetry index.
Psychopathology was assessed with the Positive and Negative Syndrome Scale. Acute ketamine administration in healthy volunteers
led to similar effects on cognition and psychopathology as observed in ﬁrst-episode and chronic schizophrenia patients. However,
the effects of ketamine on high-frequency oscillations and their connectivity proﬁle were not consistent with these observations.
Ketamine increased amplitude and frequency of gamma-power (63–80Hz) in occipital regions and upregulated low frequency
(5–28 Hz) activity. Moreover, ketamine disrupted feedforward and feedback signalling at high and low frequencies leading to
hypo- and hyper-connectivity in thalamo-cortical networks. In contrast, ﬁrst-episode and chronic schizophrenia patients showed a
different pattern of magnetoencephalographic activity, characterized by decreased task-induced high-gamma band oscillations and
predominantly increased feedforward/feedback-mediated Granger causality connectivity. Accordingly, the current data have impli-
cations for theories of cognitive dysfunctions and circuit impairments in the disorder, suggesting that acute NMDAR hypofunction
does not recreate alterations in neural oscillations during visual processing observed in schizophrenia.
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Introduction
Dysfunctions in cognitive and perceptual processes are a
pervasive feature of schizophrenia that strongly impact on
functional outcomes in the majority of patients (Green,
1996). Because no effective treatments are currently avail-
able that improve cognitive deﬁcits, identiﬁcation of circuit
mechanisms that are amenable to novel pharmacological
and behavioural interventions is a key priority of current
research.
One hypothesis that has received considerable attention is
the possibility that cognitive impairments in schizophrenia
are the results of an altered balance between excitation and
inhibition (Lewis and Moghaddam, 2006; Uhlhaas and
Singer, 2012; Krystal et al., 2017). During normal brain
functioning, effective inhibition is mediated by different
classes of -aminobutyric acid (GABA)ergic interneurons
(Tremblay et al., 2016) that regulate the activity of pyram-
idal cells through controlling their spike-timing and syn-
chronization (Cobb et al., 1995; Whittington et al.,
1995). This coordinated interplay leads to the emergence
of rhythmic ﬂuctuations in excitability or neural oscillations
(Wang and Buzsaki, 1996; Traub et al., 2004; Sohal et al.,
2009) that establish coherent information transfer between
and within brain regions that underlies cognition and be-
haviour (Fries, 2015).
Recent evidence has assigned a critical role to the
N-methyl-D-aspartate receptor (NMDAR) in the explanation
of cognitive deﬁcits and impaired neural dynamics in schizo-
phrenia (Kantrowitz and Javitt, 2010; Anticevic et al.,
2012b; Gonzalez-Burgos and Lewis, 2012). At the circuit
level, blockade of NMDARs leads to a reduction of inter-
neuron activity but an increase in ﬁring rates of pyramidal
cells (Homayoun and Moghaddam, 2007), suggesting a dis-
inhibition of neural outputs that could underlie the cognitive
deﬁcits observed following acute NMDAR administration.
Several mechanisms for changes in excitation and inhib-
ition balance have been proposed, which include a speciﬁc
role of NMDARs on parvalbumin-positive cells (Kinney
et al., 2006), but also other subclasses of interneurons
(Jadi et al., 2016) as well as presynaptic effects of
NMDARs (Pafundo et al., 2018). The potential direct
and indirect interactions of NMDARs with parvalbumin-
positive cells is of particular interest as parvalbumin-posi-
tive interneurons are prominently involved in the gener-
ation of gamma-band (30–100Hz) oscillations through
rhythmic inhibition of pyramidal cells (Sohal et al., 2009)
and have been found to be reduced in schizophrenia post-
mortem tissue (Hashimoto et al., 2008).
At the macroscopic scale, invasive electrophysiological
data indicate that acute administration of NMDAR antag-
onists, such as ketamine, lead robustly to elevated gamma-
band power in cortical (Pinault, 2008) and subcortical
structures (Hakami et al., 2009; Kocsis, 2012). In contrast,
low-frequency activity at delta and theta-bands show less
consistent effects with evidence for both up- and downre-
gulation of oscillatory activity following ketamine adminis-
tration but also other NMDA-antagonists, such as MK-801
(Hunt and Kasicki, 2013). However, there are data to sug-
gest that the upregulation of high-frequency oscillations is
observed predominantly during acute NMDAR hypofunc-
tion, while chronic administration of ketamine, for ex-
ample, leads to a reduction of gamma-band oscillations
(McNally et al., 2013; Ahnaou et al., 2017).
The modulation of neural oscillations through NMDAR
antagonists and its compatibility with ﬁndings in schizo-
phrenia is important as aberrant rhythmic activity, espe-
cially at gamma-band frequencies, has been implicated as
a potential pathophysiological mechanism in the disorder
that could account for the pervasive cognitive deﬁcits and
certain symptoms (Uhlhaas and Singer, 2010; Lewis et al.,
2012). Speciﬁcally, there is evidence to suggest that acute
administration of ketamine reproduces many of the clinical
symptoms of schizophrenia and cognitive deﬁcits in healthy
volunteers (Krystal et al., 1994) as well as impairments in
electrophysiological parameters, such as in mismatch nega-
tivity (Umbricht et al., 2000; Schmidt et al., 2013) and
corollary discharge (Kort et al., 2017). More recent evi-
dence has also highlighted that physiological alterations
induced by ketamine in functional MRI (Anticevic et al.,
2012b; Kraguljac et al., 2017) may resemble the alterations
in resting state data observed in early stage schizophrenia
but not in chronic schizophrenia (Anticevic et al., 2015a),
suggesting that acute NMDAR hypofunctioning could pro-
vide a pharmacological model relevant for understanding
the pathophysiology of schizophrenia with potentially
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important treatment implications. Accordingly, it is critical
to examine whether the spectral signatures induced by
NMDAR antagonists, such as ketamine, are compatible
with electrophysiological alterations observed in schizo-
phrenia to further validate the NMDAR hypothesis of
schizophrenia.
To systematically test this hypothesis, we investigated the
effects of a sub-anaesthetic dose of ketamine on gamma
band (30–100Hz) oscillations and functional connectivity
in a visual paradigm that elicits robust high-frequency os-
cillations with excellent test-retest reliability in controls
(Hoogenboom et al., 2006; Tan et al., 2016). In addition,
we also assessed activity at theta (4–8Hz), alpha (8–12Hz)
and beta (13–30Hz) bands and directed functional con-
nectivity in thalamo-cortical circuits. Previous preclinical
data (Dawson et al., 2013; Anderson et al., 2017) and
studies with human participants (Rivolta et al., 2015)
have indicated that NMDARs prominently dysregulate
activity in thalamo-cortical networks. Moreover, in schizo-
phrenia, both functional (Woodward et al., 2012; Anticevic
et al., 2015b) as well as anatomical alterations in thalamo-
cortical circuits (Wagner et al., 2015) have been observed,
highlighting the importance of further identifying patho-
physiological mechanisms that give rise to aberrant infor-
mation processing.
Ketamine-induced changes in spectral power and func-
tional connectivity were compared with magnetoencephalo-
graphy (MEG) data obtained from a sample of patients
with chronic schizophrenia as well as patients experiencing
their ﬁrst-episode of psychosis (FEP) to allow for a com-
parison with altered neuronal dynamics induced by
NMDAR hypofunctioning. Based on extensive evidence
highlighting reductions of sensory-induced gamma band os-
cillations during auditory and perceptual processing in
schizophrenia (Kwon et al., 1999; Spencer et al., 2008;
Sun et al., 2013; Grent-’t-Jong et al., 2016; Thune et al.,
2016), we hypothesized that acute administration of keta-
mine in healthy volunteers would lead to a reduction in the
power of task-related gamma-band oscillations. In addition,
we expected that ketamine would recreate patterns of func-
tional connectivity in schizophrenia and FEP, providing fur-
ther support for the NMDAR hypothesis of schizophrenia.
Materials and methods
Participants
Three samples of participants were recruited for this study.
The ﬁrst group comprised 14 healthy participants who were
administered a sub-anaesthetic dose of ketamine. The study
followed a single-blind, randomized, placebo-controlled, cross-
over design. An experimental session started with either a
bolus injection of 10mg S-ketamine (ketamine condition) or
10ml of NaCl 0.9% (placebo condition). This was followed
by continuous intravenous infusion of 0.006mg S-ketamine
per kg body weight per minute in the ketamine or continuous
infusion of NaCl 0.9% in the placebo condition. During the
45min of continuous infusion, participants performed a visual
task that robustly elicits high-frequency oscillations
(Hoogenboom et al., 2006). MEG data obtained during resting
state recordings have been published previously (Rivolta et al.,
2015). Following the MEG recordings, the Positive and
Negative Syndrome Scale (PANSS) (Kay et al., 1987) was ad-
ministered. Patients were also rated on the item ‘inappropriate
affect’, which allowed for a score on the factor ‘disorganiza-
tion’ (Cuesta and Peralta, 1995). Screening procedures
involved ECG, vital signs, blood test, drug tests and the
Structured Clinical Interview for DSM (SCID) for possible
signs of psychosis.
The second group comprised a sample of antipsychotic,
medication-naı¨ve patients with FEP (n = 10: n = 8 schizophre-
nia, n = 1 schizoaffective disorder and n = 1 schizophreniform
disorder), recruited from NHS services in Glasgow and
Edinburgh as well as from the general population. Ten age-
and gender-matched healthy control subjects were recruited
from the local community (Table 1).
The third group comprised 16 patients with chronic schizo-
phrenia recruited from the in- and outpatients units of the
Department of Psychiatry, Goethe-University, Frankfurt am
Main, Frankfurt, Germany. All schizophrenia patients met
DSM-IV criteria for schizophrenia and were on stable antipsych-
otic treatment. Analysis of spectral power data from this sample
were published previously (Grent-‘t-Jong et al., 2016). Sixteen
age- and gender-matched healthy controls were recruited from
the local community (Table 1).
The study was carried out according to the Declaration of
Helsinki and approved by the ethical committees of the Goethe
University Frankfurt, Germany, and NHS Greater Glasgow
and Clyde. Written informed consent was obtained after par-
ticipants received and agreed to a complete description of the
study protocol. The study was registered as a clinical trial
(PHARMASYN; EudraCT-Nr: 2011-002937-21).
Stimuli and task
The visual task paradigm (Fig. 1A) was modiﬁed after
Hoogenboom et al. (2006). On each trial, participants received
an inward moving circular sine wave grating (visual angle: 5;
spatial frequency: two cycles per degree; contrast: 100%). An
LCD projector located outside the magnetically shielded MEG
room projected the stimuli onto the screen via two front-sil-
vered mirrors, controlled by Presentation software
(Neurobehavioral Systems). The participants’ task was to
press a response button after detecting a speed increase of
the inward moving grating, which occurred randomly between
750 and 3000ms post-stimulus onset (no-acceleration catch
trials occurred on 5% of the trials). Response feedback
was provided on the screen at the end of each trial.
Neuroimaging
MEG data during ketamine administration and from patients
with chronic schizophrenia were acquired using a 275-sensor
whole-head system (Omega 2005, VSM MedTech Ltd) with a
sampling rate of 600Hz in a synthetic third order axial gradi-
ometer conﬁguration. For the FEP sample, MEG data were
acquired, using a 248-channel 4D-BTI whole-head magnetom-
eter system (MAGNES

3600 WH, 4D-Neuroimaging),
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recording at a sampling frequency of 1017.25 Hz, ﬁltered
online between DC and 400Hz.
Recordings with movements 45mm were excluded from
the analysis. A high-resolution anatomical MRI scan was
acquired for each participant on a 3 T Siemens Trio scanner,
using a 3D-MPRAGE sequence (160 slices, voxel size:
1  1  1mm; ﬁeld of view: 256mm, repetition time:
2300ms, echo time: 3.93ms), with markers placed at the
same locations as the sensors used for recording head
position in the MEG. These markers were used for
subsequent co-registration of the MEG data to the anatom-
ical T1 image.
MEG data analysis
MEG data were analysed with MATLAB using the open-
source Fieldtrip Toolbox (Oostenveld et al., 2011). Trials
were deﬁned as non-overlapping data segments starting
1000ms before stimulus onset until 1800ms post-stimulus
onset. Power line ﬂuctuations were removed by using a
Table 1 Demographic, behavioural and psychopathological data
Placebo SEM Ketamine SEM Statistics
Age, years 29  0.9 –
Gender 12 male / 2 females –
PANSS scores
Negative 8.0 0.6 13.5 1.0 t(13) = 5.0, P5 0.0001
Excitement 5.4 0.3 6.8 0.5 t(13) = 2.9, P5 0.0015
Cognitive 5.4 0.3 10.5 0.7 t(13) = 7.4, P5 0.0001
Positive 4.1 0.1 7.2 0.5 t(13) = 6.8, P5 0.0001
Depression 5.6 0.2 10.5 0.4 t(13) = 10.7, P5 0.0001
Disorganization 3.1 0.1 5.8 0.6 t(13) = 4.9, P5 0.0001
Total 35.7 0.9 60.1 2.3 t(13) = 11.6, P5 0.0001
Behaviour
Mean RT, ms 564 16.8 645 18.1 F(1,13) = 18.4, P = 0.001
Accuracy, % hits 92.5 1.1 68.7 3.3 F(1,13) = 71.6, P5 0.0001
MEG trials, n 349 20.6 353 19.2 n.s.
Controls FEP
Age, years 23.1 1.0 23.2 1.3 n.s.
Gender 5 males / 5 females 5 males / 5 females –
PANSS scores a
Negative – – 13.8 0.9 n.s.
Excitement – – 7.7 1.1 n.s.
Cognitive – – 18.0 2.0 t(23) = 3.9, P = 0.002
Positive – – 19.1 2.1 t(23) = 3.9, P = 0.002
Depression – – 12.0 1.5 n.s.
Total – – 70.6 5.5 t(23) = 2.9, P = 0.011
Behaviour
Mean RT, ms 514 20.6 575 28.6 F(1,9) = 5.5, P = 0.044
Accuracy, % hits 92.9 1.2 87.1 3.6 n.s.
MEG trials, n 225 6.3 221 9.4 n.s.
Controls Chronic schizophrenia
Age, years 30.8 8.0 34.1 10.6 n.s.
Gender 10 males / 6 females 10 males / 6 females –
PANSS scores –
Negative – – 14.3 1.6 –
Excitement – – 6.9 0.7 –
Cognitive – – 9.6 0.7 –
Positive – – 9.9 1.0 –
Depression – – 11.3 0.7 –
Total – – 51.9 3.4 –
Behaviour
Mean RT, ms 572 52.0 596 50.0 n.s.
Accuracy, % hits 94.7 1.0 82.5 3.1 F(1,15) = 129.3, P5 0.001
MEG trials, n 322 23.6 336 27.9 n.s.
aIndependent-sample t-tests, 1000 samples bootstrapping applied: PANSS scores, FEP versus schizophrenia.
n.s. = not significantly different; RT = response times.
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discrete 50Hz Fourier transform ﬁlter (including the ﬁrst two
harmonics). Trials containing muscle artefacts or sensor
(SQUID) jumps were discarded using semi-automatic artefact
rejection routines. Artefacts due to eye blinks, eye movements
and the heartbeat signal were removed using independent
component analysis decomposition and removal strategies.
Furthermore, data were downsampled to 300Hz.
All analyses were conducted on ‘virtual channel’ recon-
structed MEG data. Linearly constrained minimum variance
(LCMV) beamformer spatial ﬁlters (Van Veen et al., 1997)
were used to ﬁrst reconstruct the MEG data from MNI
source locations corresponding to centroids of 18 of 116 avail-
able AAL atlas regions (Tzourio-Mazoyer et al., 2002).
Fourteen regions were included in the power analyses: 12 cov-
ering striate and extra-striate visual-cortical areas based on
prior ﬁndings (Hoogenboom et al., 2006; Tan et al., 2016)
and two (bilateral) thalamic regions. For analyses of Granger
causality connectivity, four additional nodes were included,
covering left and right precuneus and posterior cingulate
gyrus, posterior regions involved in attention and top-down
control (Dosenbach et al., 2008; Heilbronner and Platt, 2013).
Time-frequency power representations (TFRs) were com-
puted on the 12 occipital and two thalamic LCMV recon-
structed time-series, using a sliding window Fast Fourier
Transform (FFT) approach with a ﬁxed window of 225ms
and a step size of 50ms across the length of the epochs.
Power of all frequencies between 1 and 90 Hz were estimated
based on data padded up to the 4 s, using a frequency reso-
lution of 1 Hz, and multiplying the data with a Hanning taper
before averaged power estimation. All analyses focused on task
activity from the latency window between the initial evoked
response and ﬁrst potential speed change of the stimulus (350–
750ms). Statistically signiﬁcant frequency ranges for condi-
tion and group effects (see below) were estimated unbiased
statistically from the full range of estimated frequencies
(1–90 Hz).
Analyses ﬁrst focused on contrasting task-induced activity
(350–750ms post-stimulus) with prestimulus activity (500
to 100ms) separately for ketamine and placebo conditions
(Task effects). Subsequently, Condition effects of ketamine
were tested directly by contrasting with TFR data from the
placebo condition. For the FEP and schizophrenia groups,
baseline-corrected task-induced activity was contrasted with
data from their matched control participants (Group effects).
To address changes in directed functional connectivity,
Granger causality estimates were computed across all 18
nodes. Granger causality is a technique used to assess directed,
functional interactions between different brain regions and
provides directional information about interareal communica-
tion (Seth et al., 2015). Granger causality estimates were com-
puted using a non-parametric approach, including spectral
density matrices estimated directly from Fourier transformed
data (350–750ms) in the 0–149Hz range (Hanning tapered,
frequency smoothing of 4 Hz, padded to 4 s), followed by
Figure 1 Psychopathology and behavioural performance. (A) Paradigm: participants detect increase in speed of inward moving grating
(indicated by red arrows), after which the trial ends and feedback is provided. (B) Means and standard error of means for scores on PANSS
ratings. Ketamine significantly increased all PANSS ratings (P5 0.0015 for excitement subitems and P5 0.001 for all others). Largest increases in
symptom severity were seen for cognitive and positive symptoms (also expressed in total scores) in ketamine versus placebo condition and first-
episode versus schizophrenia patients and FEP patients versus ketamine condition (all P5 0.001). (C) Mean response times (RTs, top) and
response accuracy (bottom) during the inward moving grating task for the different conditions/groups. Significantly slower responses were
recorded for ketamine compared to placebo in healthy individuals (P = 0.001), and between first-episode patients and their controls (P = 0.044).
Response accuracy was significantly lower after ketamine infusion (P5 0.0001) compared to placebo, and in patients with chronic schizophrenia
compared to controls (P5 0.001).
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matrix factorization and variance decomposition. For complex
spectral data, this approach has the advantage of fewer as-
sumptions and lacks the shortcomings of parametric
approaches using autoregressive modelling (Mitra and
Pesaran, 1999; Dhamala et al., 2008).
To determine the alterations in feedforward (FF) versus feed-
back (FB) activity, we computed the directed asymmetry index
(DAI; Bastos et al., 2015; Michalareas et al., 2016) for all
signiﬁcant projections, using the following formula:
DAIðAtoBÞ ¼ ½GCðAtoBÞ GCðBtoAÞ=½GCðAtoBÞ þGCðBtoAÞ ð1Þ
A positive value indicates that the connection A to B is pre-
dominantly feedforward, whereas a negative DAI indicates
that the ﬂow of information is predominantly feedback. The
human Granger causality (GC)-derived DAI index obtained
from MEG data has been shown to correlate strongly
with SLN values derived from macaque retrograde tracing
data (SLN equals the number of supragranular neurons
normalized by the number of supra- and infragranular
neurons that give rise to a projection from areas AtoB)
(Michalareas et al., 2016).
Statistical analysis
Both condition-speciﬁc Task effects of ketamine and placebo
and their difference (Condition effects: ketamine versus pla-
cebo), were statistically evaluated for data across the 12 oc-
cipital cortex regions of interest, and separately, for the left
and right thalamus, using data averaged over time points of
interest. Statistical testing included non-parametric Monte-
Carlo permutation dependent t-test statistics (1500 permuta-
tions) and cluster-based correction for multiple comparisons
(P5 0.05, two sided).
Granger causality estimates were tested using a similar stat-
istical approach, including Granger causality data averaged
within two frequency bins: (i) a low-frequency (5–28 Hz)
range; and (ii) gamma-band range (63–80Hz), corresponding
to the frequencies of signiﬁcant effects of ketamine on power
estimates. For the group comparisons between FEP and schizo-
phrenia groups versus controls, independent t-tests were used.
Output of the ﬁrst-level permutation statistics were in addition
false discovery rate (FDR)-controlled for type I errors by ac-
cepting only those connections that exceeded the number of
signiﬁcant connections (n = 15) expected by chance at our
alpha level of 0.05. Furthermore, changes in PANSS score es-
timates were assessed using paired-sample t-tests for ketamine
versus placebo data and independent-sample t-tests (both 1000
samples bootstrapped) for the contrast between FEP and
schizophrenia groups. Behavioural performance was tested
with repeated-measures ANOVA in a within-subject design.
Finally, to assess Group effects, data from each main group
(ketamine, FEP, schizophrenia) were z-normalized with respect
to data from their respective control group and submitted to a
one-way ANOVA using 1000 samples bootstrapping,
95% conﬁdence interval (CI), and least signiﬁcant difference
(LSD) for multiple correction of post hoc pairwise
comparisons.
Effect sizes
Cohen’s d effect sizes were computed for both power and
Granger causality analyses, separately per group. For the
ketamine group, these were computed as the difference
between the means of the ketamine and placebo conditions,
divided by the pooled standard deviation (SD) across con-
ditions. For the patient groups, effect sizes were obtained
through the difference between the means of the patient
group and their respective controls, divided by the control
group’s SD.
Data availability
The datasets generated during and/or analysed during the cur-
rent study are available from the corresponding author on
reasonable request.
Results
Behavioural data: ketamine
PANSS data (n = 14) showed that ketamine signiﬁcantly
increased scores on all six subscales (Fig. 1B and Table 1).
Behavioural responses (Fig. 1C) indicated that ketamine admin-
istration signiﬁcantly increased response times [F(1,13) = 18.4,
P = 0.001, mean response times placebo = 564  16.8ms
(SEM) and ketamine = 645  18.1 ms] while signiﬁcantly
decreasing accuracy [F(1,13) = 71.6, P50.0001, pla-
cebo = 92.5  1.1%, ketamine = 68.7 3.3%].
Behavioural and psychopathology
data: FEP and chronic schizophrenia
The FEP group had signiﬁcantly elevated total PANSS rat-
ings and increased scores on the ‘Positive’ and ‘Cognitive’
factors compared to chronic schizophrenia patients (Fig. 1B
and Table 1). Furthermore, additional one-way ANOVAs
revealed that the elevated PANSS Positive and Cognitive
factor scores in patients with FEP, but not in patients
with schizophrenia, differed signiﬁcantly (P5 0.05,
Bonferroni corrected) from those observed following keta-
mine administration in healthy individuals
[Group  PANSS Cognitive: F(2,38) = 15.3, P5 0.0001,
Group  PANSS Positive: F(2,38) = 24.6, P5 0.0001].
Behavioural performance (Fig. 1C) in patients with FEP
and with chronic schizophrenia was impaired compared to
their age- and gender-matched healthy control participants
(Table 1). The FEP group had slower response times
[F(1,9) = 5.5, P = 0.044, mean response times  standard
error of the mean (SEM) FEP = 575  28.6ms and
Controls = 514  20.6 ms], whereas patients with schizo-
phrenia were characterized by reduced response accuracy
[F(1,15) = 129.3, P5 0.001, schizophrenia = 82.5  3.1%,
Controls = 94.7  1.0%]. At the second-level, mean response
times and response accuracy were similar across groups.
MEG data
Ketamine spectral power
Condition-speciﬁc effects revealed signiﬁcantly increased
gamma-band power in the occipital regions of interest in
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both ketamine and placebo conditions, but with a slight
difference in bandwidth extending into a higher gamma
range under ketamine challenge (placebo: 50–69Hz,
Tsum = 59.3, P = 0.004; ketamine: 50–79Hz, Tsum = 91.3,
P = 0.002) (Fig. 2B, C and Table 2). A comparable spectral
proﬁle was observed in the left and right thalamus regions
of interest (Fig. 2B). However, the spectral-power modula-
tion in thalamic regions of interest was weaker than occipi-
tal regions and, as a result, the task effects were not
signiﬁcant at gamma-band frequencies (Fig. 2C).
In frequencies 550 Hz, the characteristic desynchron-
ization at alpha/beta-band frequencies was found only for
the placebo condition in occipital regions of interest
(Fig. 2B and C; 13–23Hz: Tsum = 25.9, P = 0.044) and
in the left and right thalamus [Fig. 2B and C; left thalamus
(8–23Hz), Tsum =  29.9, P = 0.004, right thalamus (11–
20Hz), Tsum =  17.4, P = 0.034]. In the ketamine condi-
tion, an additional increase in spectral power in the right
thalamus in the 1–5-Hz range was observed (Fig. 2C;
Tsum = 15.8, P = 0.022).
The contrast ketamine versus placebo condition con-
ﬁrmed the ketamine-induced shift to increased higher
gamma band activity (63–80Hz) in the occipital regions
of interest (Tsum = 60.8, P = 0.03, d = 0.88), as well as the
upregulation of low frequency activity in the alpha/beta
range in both occipital channels (5–28Hz: Tsum = 107.8,
P = 0.004, d = 1.12), left thalamus (6–30Hz: Tsum = 105.1,
P = 0.002, d = 1.31) and right thalamus (6–20Hz:
Tsum = 63.0, P = 0.002, d = 0.99).
Ketamine functional connectivity
Ketamine induced widespread changes in Granger causal-
ity values between thalamo-cortical and cortico-cortical
connections, with Granger causality patterns characterized
by predominantly hypo-connectivity (Fig. 4 and Table 3),
involving both lower (5–28Hz) and higher frequencies
(63–80 Hz).
For thalamo-cortical interactions, ketamine signiﬁcantly
(d = 1.21) decreased connectivity in the lower-frequency
range with the precuneus, posterior cingulate gyrus and infer-
ior occipital gyrus. In the higher-frequency range, a signiﬁcant
increase (d = 0.71) was observed in thalamo-cortical connect-
ivity with precuneus and calcarine ﬁssure. Cortical-cortical
connectivity was decreased in strength for both lower
(d = 1.42) and higher frequencies (d = 0.64) across a wide
range of occipital-parietal connections (Table 4).
In regards to the effect of ketamine on feedforward-
versus feedback-mediated thalamo-cortical and cortico-cor-
tical connectivity, we observed alterations for both feedfor-
ward and feedback processing at lower and high-
frequencies (Supplementary Table 2).
Spectral power in chronic schizophrenia and FEP
Overall, the direction of both task-induced power changes
in schizophrenia and FEP groups was different from those
seen in healthy controls during ketamine infusion (Table 2
and Fig. 3). Gamma-band power in the occipital regions of
interest was signiﬁcantly decreased in both FEP and chronic
schizophrenia groups [Table 2 (group effects): FEP versus
controls: 53–76Hz, Tsum = 55.7, P = 0.046, d = 1.49;
schizophrenia versus controls: 62–83Hz, Tsum = 57.9,
P = 0.026, d = 1.07], whereas low-frequency power was sig-
niﬁcantly increased in patients with chronic schizophrenia,
but not in patients with FEP, in occipital regions [Table 2
(Group effect): schizophrenia versus controls; 7–23Hz,
Tsum = 46.9, P = 0.032, d = 1.06] as well as in thalamic re-
gions of interest (left thalamus: 7–20Hz, Tsum = 37.2,
P = 0.034, d = 1.07; right thalamus: 8–20Hz, Tsum = 34.7,
P = 0.028, d = 1.02).
Second-level ANOVAs, using z-normalized data, revealed
a main effect of Group for both lower frequencies [5–28 Hz:
F(2,37) = 3.7, P = 0.035] and higher frequencies [63–80 Hz:
F(2,37) = 24.2, P5 0.0001]. Results from post hoc compari-
sons indicated that in the lower frequency range, this was
due to signiﬁcant power differences between ketamine and
FEP patients (P = 0.016) and between both patient groups
(FEP versus schizophrenia: P = 0.026), respectively. In the
63–80Hz range, ketamine effects on power estimates dif-
fered signiﬁcantly from those seen in both FEP
(P5 0.0001) and schizophrenia patients (P50.0001).
Functional connectivity in chronic schizophrenia and
FEP
Granger causality patterns also differed from ketamine ef-
fects by showing predominantly increased connectivity in
both FEP and chronic schizophrenia patients compared to
controls (Fig. 4, Table 3 and Supplementary Table 2). In
the FEP group, alterations in Granger causality connectivity
involved only higher frequency range thalamo-cortical and
cortico-cortical interactions. Increased thalamo-cortical sig-
nalling (d = 1.26) was observed between the thalamus and
middle occipital gyrus. Moreover, increased cortico-cortical
connectivity (d = 1.40) was present between precuneus and
superior occipital, inferior occipital and lingual gyrus, and
between the precuneus and middle occipital gyrus.
Similar to FEP patients, data from patients with chronic
schizophrenia were characterized by increased Granger
causality connectivity in both cortico-cortical and tha-
lamo-cortical circuits. In contrast to FEP patients, however,
it included also signiﬁcant upregulations in the lower-fre-
quency range. Thalamo-cortical hyper-connectivity in both
frequency ranges included connections primarily with the
precuneus (d = 0.98). Signiﬁcantly upregulated thalamo-
cortical connectivity in the high-frequency range
(d = 0.93) included connections with the posterior cingulate
gyrus and lingual gyrus. Signiﬁcant cortico-cortical hyper-
connectivity included mainly connections to and from the
precuneus and posterior cingulate gyrus with both striate
(calcarine ﬁssure, cuneus, lingual gyrus) and extrastriate
cortical regions (inferior, middle and superior occipital
gyrus), with upregulations present in both frequency
ranges (low: d = 1.24, high: d = 1.01). Further examination
revealed that 24 of 37 connections that were altered in
Ketamine and neural oscillations BRAIN 2018: 141; 2511–2526 | 2517
Downloaded from https://academic.oup.com/brain/article-abstract/141/8/2511/5055414
by University of Glasgow user
on 07 August 2018
Figure 2 Effects of ketamine on spectral power. (A) Indication of regions of interest (ROIs) used in the analysis, projected onto a
transparent MNI template brain. CAL = calcarine sulcus; CUN = cuneus; LING = lingual gyrus; SOG/MOG/IOG = superior/middle/inferior
occipital gyrus; THA = thalamus. (B) Time–frequency responses (TFRs) of AAL atlas reconstructed virtual channel data. Middle panel shows
grandaverage (n = 14) data from across 12 regions in the occipital cortex (averaged dB power changes from baseline), whereas the left and right
panels show the response in left and right thalamus, respectively. Data are time-locked to the onset of the visual grating stimulus. These TFRs
indicate the effect of Task on brain oscillations, separately for the placebo (first row) and ketamine (second row) condition, as well as their difference
(third row). Boxes placed over the third row TFRs indicate the window of interest in the analyses (350–750 ms). (C) Results of cluster-based
permutation statistics of Task effects (change from baseline: 350 to 750 ms versus 500 to 100 ms) for both conditions separately (placebo in
blue, ketamine in red) and separately for the occipital cluster (top) and left and right thalamus (bottom). Boxes (and black and grey dots) indicate t-
values within significant frequency clusters (cluster corrected, P5 0.05). (D) As in C, but for the Condition effects (ketamine versus placebo),
using dB change from baseline data from each condition. In occipital regions, ketamine significantly upregulated both high- and low-frequency
power (d = 0.88/1.12), whereas patients showed high-frequency power down regulation (FEP: d = 1.49, schizophrenia: d = 1.07), with upregulation
of low-frequency power only for chronic patients (d = 1.06). In the thalamus, low frequency power was upregulated for both ketamine and chronic
schizophrenia group (1.315 d5 0.99), but not for the FEP group.
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Table 3 Summary of significant Granger causality effects for low (5–28 Hz) and high frequency (63–80 Hz) activity,
separately for each experimental contrast (ketamine versus placebo, schizophrenia versus controls, and FEP versus
controls
Significant connections t-values P-values
Ketamine versus placebo (n = 14)
Low frequency (5–28 Hz)
Thalamo-cortical connectivity RPCUN-RTHA, LPCG-RTHA, LPCUN-LTHA, RTHA-
RIOG
2.2 to 3.4 0.0211 to 0.0001
Cortico-cortical connectivity LLING-RIOG, LCUN-LCAL, LPCG-RIOG, LSOG-LLING,
LSOG-LCAL, LIOG-RIOG, LMOG-RCUN, LMOG-
RPCUN, LSOG-LCUN, LCAL-LCUN, LMOG-RLING,
RIOG-LPCUN, LPCUN-RSOG, LMOG-RCAL, LIOG-
LCAL, LMOG-RSOG, RLING-LCUN, RIOG-LSOG,
LMOG-RPCG, RSOG-RCUN
2.0 to 3.3 0.0271 to 0.0001
High frequency (63–80 Hz)
Thalamo-cortical connectivity RCAL-LTHA, RTHA-RPCUN 2.5 to 2.8 0.0198 to 0.0130
Cortico-cortical connectivity LSOG-LPCUN, LLING-LPCUN, LIOG-LPCUN, RIOG-
LMOG
2.0 to 2.2 0.0213 to 0.0031
FEP versus controls (n = 10)
High frequency (63–80 Hz)
Thalamo-cortical connectivity LMOG-RTHA 2.8 0.0062
Cortico-cortical connectivity RSOG-LPCG, RSOG-LIOG, RMOG-RPCUN 2.5 to 3.2 0.0077 to 0.0043
Schizophrenia versus controls (n = 16)
Low frequency (5–28 Hz)
Thalamo-cortical connectivity LPCUN-LTHA, RPCUN-LTHA 2.3 to 2.9 0.0190 to 0.0030
Cortico-cortical connectivity RPCG-RIOG, RPCG-LPCUN, RPCG-LMOG, LPCG-
RPCUN, LPCUN-RCUN, RPCUN-LMOG, RPCG-
RCAL, RPCG-RMOG, LPCG-RSOG, LPCUN-RMOG,
LPCG-LCAL, LPCUN-RLING, LPCUN-RCAL, LPCG-
RIOG, LPCG-RLING, RPCG-RLING, LLING-LCAL,
LPCG-RCAL, LPCG-RMOG
2.2 to 3.7 0.0170 to 0.0010
High frequency (63–80 Hz)
Thalamo-cortical connectivity RPCG-RTHA, LPCUN-LTHA, RPCUN-LTHA, RPCG-
LTHA, RTHA-RLING
2.2 to 2.4 0.0200 to 0.0070
Cortico-cortical connectivity RPCG-LMOG, LPCG-RSOG, RPCUN-RSOG, RPCG-
LSOG, RPCG-LCUN, RPCUN-LMOG, RPCG-LLING,
LPCG-RSOG, LPCG-RCUN, LPCG-RLING, RPCG-
RLING, LPCG-RIOG
2.1 to 2.8 0.0250 to 0.0040
CAL = calcarine sulcus; CUN = cuneus; IOG = inferior occipital gyrus; LING = lingual gyrus; MOG = middle occipital gyrus; PCG = posterior cingulate cortex; PCUN = precuneus;
SOG = superior occipital gyrus; THA = thalamus; L = left hemisphere; R = right hemisphere.
Table 2 Regions of interest showing significant effects of ketamine (task and condition effects) and significant group
differences (FEP/schizophrenia versus controls) for task-induced changes in power (1–90 Hz)
ROI Contrast Frequency range Tsum-value P-value
Task effects
Occipital ROI Placebo: active versus baseline
Ketamine: active versus baseline
13–23 Hz
50–69 Hz
50–79 Hz
25.9
59.3
91.3
0.044
0.004
0.002
Left thalamus Placebo: active versus baseline 8–23 Hz 29.9 0.004
Right thalamus Placebo: active versus baseline
Ketamine: active versus baseline
11–20 Hz
1–5 Hz
17.4
15.8
0.034
0.022
Condition effects
Occipital ROI Ketamine versus placebo 5–28 Hz
63–80 Hz
107.8
60.8
0.004
0.030
Left thalamus Ketamine versus placebo 6–30 Hz 105.1 0.002
Right thalamus Ketamine versus placebo 6–20 Hz 63.0 0.002
Group effects
Occipital ROI FEP versus controls
Schizophrenia versus controls
53–76 Hz
62–83 Hz
7–23 Hz
55.7
57.9
46.9
0.046
0.026
0.032
Left thalamus Schizophrenia versus controls 7–20 Hz 37.2 0.034
Right thalamus Schizophrenia versus controls 8–20 Hz 34.7 0.028
Occipital region of interest (ROI) includes: bilateral calcarine fissure, cuneus, lingual gyrus, superior, middle and inferior occipital gyrus, Tsum = sum of all t-values of cluster of
significant frequency bins, P-values are cluster corrected across regions of interest and frequencies.
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chronic schizophrenia involved the posterior cingulate
gyrus (65% of connections).
Analyses of feedforward and feedback directionality of
connectivity revealed that in the schizophrenia group,
both feedforward and feedback connections were equally
upregulated at low and high frequencies. For the FEP
group, thalamo-cortical interactions involved preferen-
tially feedforward processes while for cortico-cortical con-
nectivity both feedforward and feedback communication
was changed.
Baseline differences
We statistically tested baseline power (500 to 100ms) in
all 18 AAL nodes and all frequencies between 1 and 90 Hz,
using Monte Carlo-based permutations and t-test statistics
(cluster-corrected for multiple comparisons) to assess
whether differences in post-stimulus activity between keta-
mine versus placebo conditions as well as for comparisons
involving chronic schizophrenia patients and FEP groups
versus controls were inﬂuenced by alterations in baseline
activity. For all comparisons, there were no signiﬁcant dif-
ferences observed.
Correlations: behavioural and
psychopathology versus MEG
spectral power and connectivity data
Pearson’s correlations were used on z-normalized data to
investigate relationships between changes in spectral power
and Granger causality connectivity changes in the low (5–
28Hz) and high frequency (63–80 Hz) range with response
times, detection rates and PANSS ratings (Supplementary
Table 3 and Supplementary Fig. 1). Bootstrapping (1000
randomizations) was applied to control for spurious
ﬁndings.
In the ketamine condition, reduced response accuracy
correlated with increased occipital gamma-band power
(r =  0.55, P = 0.041), but such a pattern was not
observed in the patient groups. Furthermore, a dissociation
between ketamine and the FEP/schizophrenia groups was
found for response times, which correlated negatively
with the gamma-band effect in the FEP group (r = 0.77,
P = 0.009) whereas the ketamine condition showed a posi-
tive correlation.
Figure 3 Comparisons of spectral power changes between ketamine, FEP and chronic schizophrenia groups. Top panels show
time–frequency response plots indicating occipital regions of interest recorded task-effect of ketamine in healthy controls (top left) and the
condition-effect between ketamine and placebo (bottom left), compared to task- and group-effects of similar task data recorded in FEP patients and
controls (middle) and in patients with chronic schizophrenia and controls (right column plots). All data were averaged across the regions of interest
indicated in the middle bottom panel, including data from left and right cuneus (CUN), calcarine fissure (CAL), lingual gyrus (LING), and superior/
middle/inferior occipital gyrus (SOG/MOG/IOG). The lower panel also shows box-plots with data from each Group contrast, z-normalized to their
respective control group [ketamine versus placebo (KETvsPLA), FEP versus controls (FEPvsCON), and schizophrenia versus controls
(SCZvsCON)]. Main effects of Group contrast were found for both low frequency range (P = 0.035) and high frequency range effects
(P5 0.0001), with significant post hoc pairwise comparisons indicated in the figures [low frequency: ketamine versus FEP (KETvsFEP), P = 0.016;
FEP versus schizophrenia (FEPvsSCZ), P = 0.026; high-frequency: KETvsFEP and KETvsSCZ, P5 0.0001].
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Increased thalamo-cortical and cortico-cortical high-
gamma Granger causality connectivity in the FEP group
correlated positively with response times (thalamo-cortical:
r = 0.71, P = 0.002, cortico-cortical: r = 0.60, P = 0.048),
whereas ketamine did not affect behaviour–connectivity re-
lationships. In the lower frequency range, upregulated
lower frequency power as well as increased thalamo-cor-
tical connectivity in the schizophrenia group correlated
with decreased accuracy (power: r = 0.56, P = 0.023, con-
nectivity: r =  0.53, P = 0.034).
We also systematically explored the relationship be-
tween PANSS scores, spectral power and connectivity
changes. The PANSS hallucination item ‘P3’ showed a
signiﬁcant negative correlation with gamma power in the
FEP group (r = 0.68, P = 0.003) and with high-gamma
thalamo-cortical connectivity upregulation following keta-
mine administration (r = 0.69, P = 0.006). On the other
hand, PANSS Cognitive and Positive score increases fol-
lowing ketamine challenge correlated negatively with low
frequency (5–28 Hz) cortico-cortical connectivity
Figure 4 Changes in functional connectivity in thalamo-cortical circuitry. Statistically significant (P5 0.05, Type I error corrected)
Granger causality changes between ketamine and placebo condition in healthy controls (left), FEP patients and controls (middle) and chronic
schizophrenia patients and controls (right) during stimulus processing, with data averaged over time (350–750 ms) and frequencies, separately for
low frequency range (5–28 Hz) and gamma-band range (63–80 Hz). Blue connections express a decrease and red connections an increase in
strength of connectivity between groups. Thalamo-cortical connectivity was significantly decreased in the lower frequency range for ketamine
(d = 1.21) and Schizophrenia group (d = 0.98), and was significantly stronger in the high frequency range for all groups (ketamine d = 0.71, FEP
d = 1.26, schizophrenia d = 0.93). Cortico-cortical connectivity, however, was decreased following ketamine infusion in both the low- (d = 1.42)
and high-frequency range (d = 0.64), but was increased in the low-frequency range in patients with schizophrenia (d = 1.24), and increased in the
higher range in both FEP (d = 1.40) and schizophrenia (d = 1.01) patients. CUN = cuneus; CAL = calcarine fissure; LING = lingual gyrus;
PCG = posterior cingulate gyrus; PCUN = precuneus; SOG/MOG/IOG = superior/middle/inferior occipital gyrus; THA = thalamus.
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decreases (Cognitive: r = 0.57, P = 0.033, Positive:
r = 0.48, P = 0.050).
Discussion
The current study attempted to systematically explore the
commonalities between the effects of a sub-anaesthetic dose
of ketamine on neural oscillations during visual processing
in thalamo-cortical networks and alterations in chronic
schizophrenia and FEP patients. Recent evidence has high-
lighted the crucial contribution of thalamo-cortical inter-
actions towards the pathophysiology of schizophrenia
(Woodward et al., 2012; Anticevic et al., 2015b), which
is supported by extensive evidence on the impact of
NMDAR hypofunctioning on thalamo-cortical circuits
(Santana et al., 2011; Dawson et al., 2013; Hoﬂich et al.,
2015; Anderson et al., 2017; Pratt et al., 2017) and the
relationship between NMDARs and feedback processing
during visual perception (Self et al., 2012; van Loon
et al., 2016).
Our ﬁndings could not support the main hypotheses.
While our data demonstrate that ketamine profoundly im-
pacts upon the power and spectral interactions of neural
oscillations in thalamo-cortical networks, the effects of
ketamine on both the amplitude of gamma-band oscilla-
tions as well as on functional connectivity were largely op-
posite to the alterations observed in both FEP and chronic
schizophrenia patients, suggesting that the acute NMDA
hypofunction may not fully account for altered neurody-
namics in the disorder.
Consistent with previous reports (Krystal et al., 1994),
ketamine administration led to an increase in psychopath-
ology as well as reduced detection rates and elevated re-
sponse times in healthy volunteers. Increased PANSS
ratings and impaired behavioural performance were accom-
panied by an increase in 60–80Hz power in occipital cor-
tices. These ﬁndings are consistent with data from auditory
perception (Hong et al., 2010), visual cortex (Shaw et al.,
2015) and resting state MEG recordings (Rivolta et al.,
2015), indicating that ketamine upregulates rhythmic activ-
ity at gamma-band frequencies.
Moreover, we found elevated theta, alpha and beta
power, which is typically suppressed during visual tasks,
suggesting a disinhibition of neural circuits during keta-
mine. This effect was prominent not only in occipital re-
gions but also in thalamus, a region with a high
concentration of NMDARs (Monaghan and Cotman,
1985). In addition to this ﬁnding, ketamine also increased
1–5Hz oscillations in the right thalamus, which has been
observed in invasive electrophysiological studies (Zhang
et al., 2012). While observations in deep brain structures
with MEG can be challenging because of the decay of the
magnetic ﬁeld, the large effect size of this modulation in
our data (Table 4) and the overlapping spectral proﬁle of
thalamic channels with cortical generators support the
feasibility of MEG in combination with individual anatom-
ical information to assess thalamic signals (Attal et al.,
2007; Roux et al., 2013).
One novel observation of the current study is the exam-
ination of changes in directed, spectral interactions follow-
ing ketamine administration. Recent evidence suggests that
frequency-speciﬁc, hierarchical networks can be recon-
structed from MEG data (Michalareas et al., 2016),
which mirror ﬁndings obtained from invasive electrophysio-
logical recordings (Bastos et al., 2015). Accordingly, this
approach allowed us to determine whether ketamine im-
pacted speciﬁcally on feedback communication given the
contribution of NMDARs in this process (Self et al.,
2012) and the role of beta/alpha-band oscillations in feed-
back processing during visual and attentional tasks
(Buschman and Miller, 2007; van Kerkoerle et al., 2014;
Michalareas et al., 2016).
Our data, however, only partially support this framework.
Overall, we found that ketamine reduced both feedforward
and feedback communication especially at lower frequencies,
while in the 63–80Hz frequency range, enhanced thalamo-
cortical connectivity with parietal and early visual cortex
was found. In contrast, cortico-cortical was decreased
across a wide range of occipital-parietal connections.
Table 4 Summary table of main findings and Cohen’s d effect sizes
Ketamine versus
placebo
FEP versus
controls
Schizophrenia
versus controls
Oscillatory power changes
Occipital cortex: 63–80/53–76/62–83 Hz " 0.88 # 1.49 # 1.07
Occipital cortex: 5–28/7–23 Hz " 1.12  " 1.06
Left thalamus: 6–20/7–20 Hz " 1.31  " 1.07
Right thalamus: 6–30/8–20 Hz " 0.99  " 1.02
Granger causality connectivity changes
Low frequency (5–28 Hz)
Thalamo-cortical connectivity # 1.21  " 0.98
Cortico-cortical connectivity # 1.42  " 1.24
High frequency (63–80 Hz)
Thalamo-cortical connectivity " 0.71 " 1.26 " 0.93
Cortico-cortical connectivity # 0.64 " 1.40 " 1.01
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Importantly, the analysis of MEG data from a sample of
FEP and chronic schizophrenia patients revealed a strik-
ingly different pattern both in regards to the direction of
effects in spectral power and connectivity (Table 4 and
Supplementary Table 2). Consistent with prior data high-
lighting an impairment in the generation of gamma-band
oscillations during auditory (Kwon et al., 1999) and visual
paradigms (Spencer et al., 2003; Sun et al., 2013), both
FEP and schizophrenia groups showed a pronounced re-
duction in the 50–80Hz power range in occipital cortex.
Further studies need to address the question, however,
whether there is a causal link between impaired gamma-
band oscillations and cognitive deﬁcits in schizophrenia, for
example, through the use of frequency-speciﬁc brain stimu-
lation (Thut et al., 2011).
For low frequency power (5–28 Hz), we found that both
the ketamine condition as well as the chronic schizophrenia
group showed a comparable upregulation of spectral
power. During sensory processing, activity at theta, alpha
and beta frequencies are typically suppressed, indicating
desynchronization to facilitate processing of relevant stimu-
lus information (Pfurtscheller and Lopes da Silva, 1999;
Hoogenboom et al., 2006). The ﬁnding in chronic schizo-
phrenia patients suggests that this mechanism is impaired,
which could potentially interfere with processing of rele-
vant stimulus material as indicated by the negative relation-
ship between accuracy and low frequency power
(Supplementary Table 3).
Overall, the differential ﬁndings in regards to gamma-
band power and low frequency activity suggest that impair-
ments in high frequency activity could represent a trait
marker in schizophrenia as both FEP and chronic schizo-
phrenia patients were characterized by large reductions in
spectral power. In contrast, it is conceivable that low fre-
quency oscillations are a state marker that is inﬂuenced by
clinical symptoms, which expectedly differed between FEP
and chronic schizophrenia groups.
There were also notable differences between clinical
groups with regards to the pattern of directed connectivity.
In the schizophrenia group, Granger causality patterns were
exclusively characterized by hyperconnectivity that involved
both feedforward and feedback connections at low and
high frequencies, highlighting a profound dysregulation of
neuronal communication. These alterations seemed to in-
volve preferentially connections with the posterior cingulate
gyrus, a prominent node of the default mode network
(DMN) (Raichle et al., 2001), which is typically deactivated
during task-relevant processing. Previous evidence from
functional MRI data in schizophrenia patients suggests
that the switching between the DMN and attention net-
works is impaired (Anticevic et al., 2012a).
Compared to patients with chronic schizophrenia, alter-
ations in Granger causality connectivity involved only the
gamma-band range, which showed a mixture of thalamo-
cortical and cortico-cortical interactions. Together with the
absence of alterations in low-frequency power in FEP-pa-
tients, these ﬁndings suggest that there may be illness-
speciﬁc alterations in neuronal dynamics that could poten-
tially indicate a progressive dysfunction during the course
of illness. However, we would like to note that these ﬁnd-
ings need to be replicated in larger samples.
Importantly, neither the alterations in task-related oscil-
lations following ketamine administration nor the power
changes in the patient samples were driven by differences
in baseline activity. This contrasts with previous ﬁndings
in preclinical studies of NMDAR antagonists on neural
oscillations (Ehrlichman et al., 2009; Saunders et al.,
2012) as well as with EEG studies in schizophrenia
(Hirano et al., 2015) that have implicated alterations in
baseline gamma-band activity for sensory processing def-
icits in schizophrenia.
Taken together, these data highlight the importance of
NMDAR mediated neurotransmission for the amplitude
and organization of spectral organization of task-related
neural oscillations. Excitation and inhibition balance is con-
sidered a crucial factor for the generation of neural oscil-
lations and interactions in hierarchical networks (Yizhar
et al., 2011). Consistent with a wealth of preclinical data
(Pinault, 2008; Sivarao et al., 2016), the current ﬁndings
highlight that the NMDAR hypofunctioning enhances the
amplitude of gamma-frequency activity and upregulates
low frequency oscillations while behavioural performance
is reduced. Accordingly, optimal information processing in
large-scale networks can be disrupted both by an excess of
gamma-band activity as well as by an impairment in the
generation of gamma-band oscillations as observed in
schizophrenia.
The current data have implications not only for under-
standing the mechanisms of spectral interactions in large-
scale networks during normal brain functioning but also
for the role of NMDAR hypofunctioning in the pathophysi-
ology of schizophrenia. We would like to note that the
impact of ketamine on the amplitude as well as spectral
interactions during task-related gamma-band oscillations
is not compatible with visually-elicited neural oscillations
in patients at an early stage of psychosis as well as in a
sample of chronic schizophrenia patients. Previous preclin-
ical (Schobel et al., 2013), resting state functional MRI data
(Anticevic et al., 2015a) and EEG studies (Umbricht et al.,
2000; Schmidt et al., 2013; Kort et al., 2017) have sug-
gested that the neural signatures induced by acute NMDA
antagonists, such as ketamine, resemble behavioural deﬁcits
and physiological alterations observed in schizophrenia, in
particular during early stages of the disorder. The current
data do not support this hypothesis and suggest instead
that alterations in task-related oscillations in schizophrenia,
in particular at gamma-band frequencies, may be not com-
patible with the effects of acute NMDAR hypofunctioning.
There are several limitations of this study that relate to
the sample size of healthy volunteers and patients with
schizophrenia or FEP as well as our pharmacological ma-
nipulation. First, we would like to note that while the study
used only moderate samples of participants, the effect sizes
for ketamine effects on power and spectral interactions as
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well for differences between controls and patient popula-
tions were consistently large (Table 4 and Supplementary
Table 3). Moreover, statistical contrasts for main effects
survived conservative statistical correction. Finally, we
would like to emphasize the consistent effects of the
visual paradigm used across groups on the modulation of
gamma-band oscillations with high signal-to-noise and ex-
cellent test-rest reliability (Tan et al., 2016).
Second, it is important to note that ketamine while acting
on NMDARs also leads to a dysregulation of serotonergic
(Li et al., 2015) and dopaminergic neurotransmission (du
Jardin et al., 2016). Accordingly, it is conceivable that the
changes in both spectral power and functional connectivity
observed in the current study are not only due to NMDA
hypofunctioning. We believe, however, that there is evi-
dence to suggest that the effects of ketamine on gamma-
band oscillations, for example, are indeed strongly
mediated by NMDARs as the effects of ketamine on
gamma-band oscillations are the result of speciﬁc actions
on NMDAR subunits (Kocsis, 2012) and serotonergic an-
tagonists, for example, do not lead to a similar dysregula-
tion of high frequency activity following NMDAR
hypofunctioning (Wood et al., 2012).
Finally, we would like highlight that the mechanisms
underlying the upregulation of gamma-band oscillations
following the administration of ketamine remain to be
determined. As highlighted previously, several scenarios
have been proposed that include the downregulation of
NMDARs on parvalbumin-positive interneurons that
could elevate the contribution of faster AMPA receptors
onto parvalbumin-positive cells, providing in turn favour-
able conditions for the generation of gamma-band oscilla-
tions (Rotaru et al., 2011). Further, upregulation of
gamma-band oscillations following ketamine administra-
tion could also target other subclasses of interneurons
(Jadi et al., 2016) as well as presynaptic effects of
NMDARs (Pafundo et al., 2018). However, differentiation
of these mechanisms will require further careful investiga-
tions into the interaction between NMDARs, different
interneuron populations as well as the contribution of
other neurotransmitter systems that could not only be rele-
vant for the understanding the role of NMDAR hypofunc-
tioning in schizophrenia but also for the generation and
mechanistic importance of neural oscillations in general.
In summary, our ﬁndings strongly support the ability of
acute ketamine to induce schizophrenia-like symptoms and
neurocognitive deﬁcits. In addition, many measures such as
low frequency oscillatory changes in both occipital cortex
and thalamus show changes in the same direction following
acute ketamine treatment versus placebo and schizophrenia
versus control. However, our ﬁndings also highlight the
dissociation between changes in gamma-band oscillations
observed following acute ketamine administration and
those seen in schizophrenia. These ﬁndings suggest that
the reductions in gamma-band activity observed in both
patients with FEP and those with chronic schizophrenia
cannot be attributed to acute NMDA receptor blockade,
but instead may reﬂect consequences of longer term
NMDAR dysfunction (McNally et al., 2013; Ahnaou
et al., 2017), or effects of ketamine mediated via non-
NMDA neurotransmitter systems.
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